SCYNEXIS Inc (SCYX) Receives Consensus Rating of “Buy” from Analysts
SCYNEXIS Inc (NASDAQ:SCYX) has been assigned a consensus rating of “Buy” from the eight brokerages that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and five have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $10.00.
Several research analysts have recently commented on SCYX shares. Zacks Investment Research cut shares of SCYNEXIS from a “buy” rating to a “hold” rating in a report on Tuesday, September 12th. Guggenheim started coverage on shares of SCYNEXIS in a report on Tuesday, October 24th. They set a “buy” rating and a $6.00 target price on the stock. Finally, ValuEngine raised shares of SCYNEXIS from a “strong sell” rating to a “sell” rating in a report on Saturday, December 9th.
Shares of SCYNEXIS (NASDAQ:SCYX) traded down $0.08 on Tuesday, hitting $1.98. 164,973 shares of the stock traded hands, compared to its average volume of 250,328. SCYNEXIS has a 12 month low of $1.52 and a 12 month high of $3.82. The company has a market capitalization of $56.55, a PE ratio of -2.44 and a beta of 0.36. The company has a debt-to-equity ratio of 0.43, a current ratio of 7.30 and a quick ratio of 7.30.
ILLEGAL ACTIVITY NOTICE: “SCYNEXIS Inc (SCYX) Receives Consensus Rating of “Buy” from Analysts” was first posted by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.watchlistnews.com/scynexis-inc-scyx-receives-consensus-rating-of-buy-from-analysts/1800422.html.
SCYNEXIS, Inc is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains.
Receive News & Ratings for SCYNEXIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SCYNEXIS and related companies with MarketBeat.com's FREE daily email newsletter.